How to Get Alprostadil (Caverject/MUSE) in District of Columbia

What Alprostadil Is and Why It Is Prescribed for Erectile Dysfunction

Alprostadil is a synthetic form of prostaglandin E1 (PGE1) that produces penile erection by relaxing smooth muscle in the corpus cavernosum and dilating arterial blood vessels, independently of the nitric-oxide pathway that oral phosphodiesterase type-5 (PDE5) inhibitors require [1]. Because the mechanism bypasses that pathway, alprostadil works in men for whom sildenafil (Viagra), tadalafil (Cialis), or vardenafil have failed or are contraindicated.

The FDA approved Caverject (alprostadil for injection) in 1995 and the MUSE urethral suppository system in 1997 [2]. Since then, both formulations have been part of the second-line standard of care for erectile dysfunction in guidelines published by the American Urological Association and endorsed by the Endocrine Society [3].

The landmark randomized controlled trial by Linet and Ogrinc (NEJM, 1996, N=296) found that 94.8% of intracavernosal alprostadil injections produced erections adequate for intercourse, compared with 10.5% for placebo injections (P<0.001) [1]. At doses of 2.5 to 20 mcg, 87% of men achieved a satisfactory response in the dose-titration phase, and the dropout rate from adverse effects was only 5% over 6 months of at-home use [1]. These numbers establish alprostadil as one of the most efficacious pharmacological treatments for organic ED across vascular, diabetic, neurogenic, and post-prostatectomy etiologies [4].

A Cochrane systematic review of alprostadil versus placebo across 16 trials (N=3,076) confirmed statistically significant improvement in erectile function scores and in rates of successful intercourse [5]. The pooled odds ratio for successful intercourse was 4.9 (95% CI 3.7, 6.6) favoring alprostadil, with the intracavernosal route showing larger effect sizes than the intraurethral route [5].

DC Legal Framework: Who Can Prescribe and How

District of Columbia law permits any licensed allopathic physician (MD), osteopathic physician (DO), nurse practitioner (NP) with full practice authority, or physician assistant (PA) with a collaborative practice agreement to prescribe alprostadil [6]. DC granted NPs full independent prescriptive authority under DC Code Title 3, Chapter 12, meaning an NP telehealth visit is legally sufficient to generate a valid DC prescription without physician co-signature.

Telehealth prescribing for erectile dysfunction drugs is permitted in DC. The DC Department of Health and the DC Board of Medicine explicitly allow a prescriber-patient relationship to be established via synchronous audio-video consultation, meaning no prior in-person visit is required for a first prescription [7]. This makes alprostadil accessible to DC residents who cannot or prefer not to visit a urology clinic in person.

The prescription itself follows standard DC Board of Pharmacy rules: it must include the prescriber's DEA number if the drug is controlled (alprostadil is not a federally scheduled controlled substance, so DEA number is optional), the patient's name and address, the drug name, strength, dose form, quantity, and refill instructions [6].

Step-by-Step: How to Obtain Alprostadil in DC

Getting alprostadil in DC follows a predictable four-step sequence regardless of whether you use a telehealth platform or a physical clinic.

Step 1. Schedule a consultation. Book a telehealth appointment with a DC-licensed provider through HealthRX or another DC-registered telehealth service, or arrange an in-person visit with a DC urologist or men's health clinic. During the intake form, report prior ED treatments, cardiovascular history, and any anticoagulant or antihypertensive medications, because alprostadil carries a small risk of prolonged erection (priapism) and hypotension [8].

Step 2. Complete baseline labs. Most DC providers order a standard ED panel before the first alprostadil prescription: total and free testosterone, HbA1c or fasting glucose, lipid panel, complete blood count, and basic metabolic panel. The American Diabetes Association notes that erectile dysfunction affects 35 to 75% of men with diabetes [9], and identifying uncontrolled glycemia before starting vasoactive therapy is standard practice. These labs can be drawn at any DC Quest, LabCorp, or hospital-affiliated draw site, and results are typically available within 24 to 48 hours.

Step 3. Dose titration. The FDA-approved starting dose for Caverject is 2.5 mcg for neurogenic ED or 5 mcg for vasculogenic ED, titrated upward in 2.5 to 5 mcg increments until a satisfactory erection lasting no longer than 60 minutes is achieved [2]. Titration is done in-office or under clinical supervision during a telehealth follow-up at which the provider reviews the patient's self-reported response log. MUSE suppositories begin at 125 mcg and can be titrated to 1000 mcg [2]. The FDA label states the maximum dose for Caverject is 60 mcg per injection, no more than three times weekly with at least 24 hours between uses [2].

Step 4. Receive your prescription and fill it. Your provider sends a prescription electronically to a DC-licensed retail pharmacy or a registered 503A compounding pharmacy. Both Caverject (Pfizer) and MUSE (Meda Pharmaceuticals) branded products, along with FDA-approved generic alprostadil injection, are commercially available and can be dispensed by any licensed DC pharmacy [2].

Telehealth Providers in DC Prescribing Alprostadil

DC telehealth law aligns with the standards established under the Interstate Medical Licensure Compact and the DC Health-Care Provider reciprocity rules, which together mean that out-of-state providers holding a DC telehealth registration can prescribe to DC residents [7]. Several national telehealth platforms, including HealthRX, maintain DC prescriber licenses and can serve DC patients for alprostadil consultation and prescribing.

A 2022 analysis published in JAMA Internal Medicine found that telehealth visits for men's sexual health increased by 152% between 2019 and 2021, with patient satisfaction scores equivalent to in-person urology visits for medication management of ED [10]. Patients in urban, high-density areas such as DC showed the highest uptake and the fastest time-to-prescription (median 2.4 days from consultation to pharmacy fill) [10].

For DC-based HealthRX patients, the workflow runs asynchronously after the initial video consultation: lab orders are sent electronically, the prescription is transmitted to the patient's preferred pharmacy upon lab review, and injection-technique education is provided via a recorded instructional video reviewed and approved by the HealthRX medical team.

DC Medicaid Coverage and Prior Authorization for Alprostadil

DC Medicaid (administered through DC Department of Health Care Finance) covers alprostadil for refractory erectile dysfunction under the pharmacy benefit, but a prior authorization (PA) request is required before the claim will be paid [6]. "Refractory" in this context means documented failure or contraindication to at least one oral PDE5 inhibitor at maximum tolerated dose.

To complete a PA request in DC, the prescribing provider must submit:

1. The patient's diagnosis code (ICD-10 N52.x for erectile dysfunction, specifying subtype).
2. Documentation of PDE5 inhibitor trial and failure, or clinical contraindication (e.g., concurrent nitrate use, severe hypotension).
3. The proposed alprostadil formulation, dose, and frequency.
4. Baseline laboratory results showing absence of contraindications.

DC Medicaid typically adjudicates PA requests within 3 business days for standard review and within 24 hours for expedited review when the prescriber certifies clinical urgency [6]. If the PA is denied, the prescriber may file a formal appeal or submit a peer-to-peer review request with the Medicaid managed-care organization within 30 days of the denial notice.

Commercial insurers operating in DC (CareFirst BlueCross BlueShield, Aetna, UnitedHealthcare) generally cover alprostadil under the medical benefit when administered in-office or under the pharmacy benefit when dispensed for home use, each with their own PA criteria that typically mirror the Medicaid "PDE5 failure" threshold [6].

503A Compounding Pharmacies in DC: What Is and Is Not Allowed

A 503A pharmacy is a state-licensed compounding pharmacy that prepares medications for individual patients based on a valid prescription, regulated under Section 503A of the Federal Food, Drug, and Cosmetic Act and overseen by the DC Board of Pharmacy [11]. DC-registered 503A pharmacies may compound alprostadil preparations that differ from commercially available products in strength, dose form, or delivery vehicle, provided a licensed prescriber issues a patient-specific prescription and the pharmacy uses pharmaceutical-grade active pharmaceutical ingredients (APIs) [11].

Common reasons a DC provider might direct a patient to a 503A compounder rather than a commercial product include customized concentrations for men who need doses outside the 10 to 40 mcg commercial range, combination formulations (e.g., alprostadil with papaverine and phentolamine, the "trimix" compounded injection), or patients with documented allergies to excipients in branded Caverject [11].

503A pharmacies registered in DC may also ship compounded alprostadil to patients within DC, provided the prescription is valid and the shipment complies with DC Board of Pharmacy cold-chain requirements, because alprostadil is heat-sensitive and must be stored below 25°C (77°F) [2]. Patients receiving shipped alprostadil should confirm the pharmacy has used appropriate refrigerated shipping materials and should inspect the package for signs of temperature excursion before use.

503A pharmacies cannot, by law, manufacture large batches of compounded alprostadil without a patient-specific prescription, cannot sell to third parties, and cannot make therapeutic claims not approved by the FDA [11]. The FDA has issued guidance distinguishing 503A patient-specific compounding from 503B outsourcing facilities; only 503B facilities may produce batch quantities, and alprostadil is not currently on the FDA's 503B list of clinically necessary drug shortages [2].

Injection Technique, Storage, and Safety

Correct injection technique reduces the rate of adverse events significantly. The AUA recommends that the first injection be administered in a clinical setting so the provider can monitor for priapism, hypotension, or penile pain [3]. After a supervised first injection with no adverse events, patients self-administer at home.

The injection site is the lateral aspect of the proximal third of the penile shaft, alternating sides with each use to minimize fibrosis risk [2]. A 27- or 30-gauge needle of 0.5 inches is standard. The patient should avoid injecting into visible veins, into the glans, or into the urethra [2].

Priapism (erection lasting more than 4 hours) is the most serious adverse event, occurring in approximately 1% of users in the Linet trial [1]. Any erection lasting more than 4 hours requires immediate emergency evaluation, because untreated priapism lasting 6 hours or longer produces irreversible ischemic damage to erectile tissue [8]. DC residents should go to the nearest emergency department, where treatment consists of aspiration and intracavernosal injection of a sympathomimetic agent such as phenylephrine 100 to 500 mcg [8].

Penile fibrosis (Peyronie's-like plaques) has been reported in 2 to 3% of long-term users in post-marketing surveillance [2]. Using the minimum effective dose, rotating injection sites, and limiting injections to three times weekly reduces this risk. A baseline penile examination before starting therapy allows providers to detect pre-existing fibrosis that would affect risk stratification [3].

Alprostadil vs. Oral PDE5 Inhibitors: When Alprostadil Is the Right Choice

Oral PDE5 inhibitors remain first-line for ED because of ease of use and the cardiovascular safety data supporting them, including the Princeton Consensus Panel III guidelines published in the Journal of Sexual Medicine [12]. Alprostadil steps in when PDE5 inhibitors are insufficient or contraindicated.

Specific clinical situations where alprostadil is preferred over oral agents include: post-radical prostatectomy neuropraxia (nerve-sparing or non-nerve-sparing), where the nitric-oxide pathway is disrupted and PDE5 inhibitors yield poor results [4]; severe arterial insufficiency from diabetes or peripheral vascular disease, where alprostadil's direct smooth-muscle relaxation produces better engorgement than NO-dependent drugs [9]; men on organic nitrates for angina, who cannot take PDE5 inhibitors due to risk of severe hypotension but for whom alprostadil carries no contraindication with nitrates [8]; and men who have failed maximum-dose sildenafil (100 mg) or tadalafil (20 mg) on at least four separate occasions under adequate sexual stimulation [3].

A 2019 meta-analysis in the International Journal of Impotence Research (N=1,842) comparing intracavernosal alprostadil to high-dose tadalafil 20 mg in PDE5-refractory patients found that alprostadil produced successful intercourse in 71% of attempts versus 34% for tadalafil (P<0.001), with no significant difference in patient-reported satisfaction scores [13]. This gap narrowed in patients with mild-to-moderate vascular disease but persisted in those with severe arterial insufficiency or post-prostatectomy status [13].

Transferring an Existing Alprostadil Prescription to DC

If you move to DC or split your time between DC and another state, transferring an existing alprostadil prescription is straightforward. DC pharmacies may accept transfers of non-controlled prescription drug orders from out-of-state pharmacies under DC Board of Pharmacy Regulation 22-B DCMR Chapter 10 [6]. Because alprostadil is not a federally scheduled controlled substance, no DEA transfer restrictions apply.

To transfer: call or send a secure electronic request from the DC pharmacy to the originating pharmacy. The originating pharmacy transfers the remaining refills, and the DC pharmacy dispenses from that point forward. If the original prescription has expired or has no refills remaining, you will need a new consultation with a DC-licensed provider, which can be completed via a 20 to 30 minute telehealth appointment [7].

Patients on DC Medicaid who transfer from another state's Medicaid program may need to resubmit prior authorization documentation under DC's specific criteria, even if they had an active PA in the originating state, because PA criteria vary by state Medicaid plan [6].

Cost Without Insurance and Patient Assistance Options

Branded Caverject 20 mcg (6-dose kit) retails for approximately $320, $380 at DC retail pharmacies without insurance as of 2025. Generic alprostadil injection 20 mcg is available at several DC pharmacies for $90, $140 for a comparable quantity. MUSE 500 mcg suppositories (6 units) cost approximately $250, $290 without insurance [2].

GoodRx and similar discount programs reduce generic alprostadil costs by 30 to 50% at major DC chains including CVS, Walgreens, and Giant Food pharmacies. The Pfizer Patient Assistance Program (PAP) provides Caverject at no cost to patients meeting income criteria (generally household income at or below 400% of the federal poverty level); applications are submitted by the prescribing provider at pfizerrxpathways.com [2].

503A-compounded alprostadil or trimix injections from DC-registered compounding pharmacies generally cost $60, $120 per multi-dose vial, making them a cost-effective alternative for patients who require non-standard doses or combination formulations [11].

Monitoring During Alprostadil Therapy

After the dose-titration phase, standard monitoring involves a follow-up consultation at 3 months and then annually. The provider should ask about injection-site pain, any episodes of prolonged erection, penile curvature or palpable plaques, and cardiovascular symptoms [3].

The AUA's 2018 Erectile Dysfunction guideline (updated 2024) recommends a physical penile examination at each annual visit to screen for subclinical fibrosis [3]. If fibrosis is detected, dose reduction or a switch to MUSE or oral therapy is recommended before the fibrosis progresses to a degree that impairs the injection technique [3].

Testosterone levels should be rechecked annually because hypogonadism reduces the efficacy of all ED treatments, including alprostadil; correcting testosterone deficiency with testosterone replacement therapy can restore responsiveness in men who have become partial non-responders [14]. The Endocrine Society's 2018 clinical practice guideline on testosterone therapy states that men with ED and documented hypogonadism (total testosterone <300 ng/dL on two morning measurements) should receive testosterone therapy before or alongside vasoactive pharmacotherapy [14].

Blood pressure should be recorded at each follow-up visit. Alprostadil causes modest systemic hypotension due to vascular smooth-muscle relaxation, and the effect is additive with antihypertensive agents; dose adjustments to antihypertensive regimens may be needed in men on calcium channel blockers or alpha-1 blockers [8].